(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of 240.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.61%.
Outlook Therapeutics's revenue in 2025 is $1,505,322.On average, 4 Wall Street analysts forecast OTLK's revenue for 2026 to be $1,320,370,500, with the lowest OTLK revenue forecast at $707,158,902, and the highest OTLK revenue forecast at $2,704,260,926. On average, 2 Wall Street analysts forecast OTLK's revenue for 2027 to be $3,803,866,366, with the lowest OTLK revenue forecast at $857,741,105, and the highest OTLK revenue forecast at $6,749,991,627.
In 2028, OTLK is forecast to generate $1,014,542,042 in revenue, with the lowest revenue forecast at $1,014,542,042 and the highest revenue forecast at $1,014,542,042.